| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (NCT02857270) | Eli Lilly and Company | 2016-09-29 |
| Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord (NCT02713269) | M.D. Anderson Cancer Center | 2016-08-29 |
| Immune Monitoring in Metastatic Melanoma (NCT04158544) | University of Regensburg | 2016-08-01 |
| RATIO: Rational Approach To Immuno-Oncology (NCT02700971) | AHS Cancer Control Alberta | 2016-06-23 |
| Imaging FDG Flare in Melanoma (NCT02791594) | Abramson Cancer Center at Penn Medicine | 2016-06-01 |
| A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma (NCT02768207) | Hoffmann-La Roche | 2016-05-23 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (NCT02595866) | National Cancer Institute (NCI) | 2016-04-04 |
| Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study (NCT02038348) | Assistance Publique Hopitaux De Marseille | 2016-02-16 |
| Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. (NCT02678741) | Elios Therapeutics, LLC | 2016-02-01 |
| Molecular Characterization of Advanced Stage Melanoma by Blood Sampling (NCT02862743) | CHU de Reims | 2016-01-14 |
| A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma (NCT02644967) | Idera Pharmaceuticals, Inc. | 2015-12-01 |
| A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (NCT02608437) | Italian Network for Tumor Biotherapy Foundation | 2015-10-01 |
| Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (NCT02360579) | Iovance Biotherapeutics, Inc. | 2015-09-24 |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (NCT02224781) | National Cancer Institute (NCI) | 2015-09-08 |
| A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT02521870) | Dynavax Technologies Corporation | 2015-09-01 |
| Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma (NCT02500576) | M.D. Anderson Cancer Center | 2015-08-07 |
| Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib (NCT02357732) | University of Pittsburgh | 2015-08-01 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies (NCT02419495) | M.D. Anderson Cancer Center | 2015-06-26 |
| Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types (NCT06075524) | Mayo Clinic | 2015-06-15 |
| Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study (NCT02424916) | Nantes University Hospital | 2015-05-26 |
| Radiotherapy & Combi in Metastatic Melanoma (NCT02392871) | Melanoma and Skin Cancer Trials Limited | 2015-05-01 |
| Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies (NCT02626065) | Hospices Civils de Lyon | 2015-04-23 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms (NCT02150369) | Duke University | 2015-02-16 |
| Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma (NCT01740557) | M.D. Anderson Cancer Center | 2015-01-28 |
| CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma (NCT02027935) | M.D. Anderson Cancer Center | 2015-01-22 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NCT02306850) | St. Louis University | 2015-01-01 |
| Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes (NCT02310451) | Centre Hospitalier Universitaire de Nice | 2014-12-01 |
| Vemurafenib and TIL Therapy for Metastatic Melanoma (NCT02354690) | Inge Marie Svane | 2014-11-01 |
| Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (NCT03176485) | University of Arizona | 2014-10-17 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma (NCT01955460) | M.D. Anderson Cancer Center | 2014-10-15 |
| Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (NCT02278887) | The Netherlands Cancer Institute | 2014-09-23 |
| A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma (NCT02177110) | Cancer Trials Ireland | 2014-09-01 |
| Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (NCT02073123) | NewLink Genetics Corporation | 2014-07-01 |
| Immunotherapy Study for Patients With Stage IV Melanoma (NCT02054520) | NewLink Genetics Corporation | 2014-06-01 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02097225) | National Cancer Institute (NCI) | 2014-05-29 |
| Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (NCT02117362) | Providence Health & Services | 2014-05-08 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists (NCT02126579) | Craig L Slingluff, Jr | 2014-05-01 |
| Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma (NCT02141542) | F. Stephen Hodi, MD | 2014-05-01 |
| Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery (NCT02097732) | University of Michigan Rogel Cancer Center | 2014-04-01 |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (NCT01989585) | National Cancer Institute (NCI) | 2014-03-24 |
| TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment (NCT01995344) | The Christie NHS Foundation Trust | 2014-03-01 |
| Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma (NCT01838200) | Ludwig Institute for Cancer Research | 2014-03-01 |
| Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (NCT01689870) | Ludwig Institute for Cancer Research | 2014-03-01 |
| Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma (NCT02142335) | California Cancer Assocaties for Research & Excellence | 2014-03-01 |
| Multicenter Tissue Registry in Melanoma (NCT05750511) | Dermatologic Cooperative Oncology Group | 2014-02-01 |
| T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma (NCT02062359) | National Cancer Institute (NCI) | 2014-02-01 |
| Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma (NCT01933061) | Celgene Corporation | 2014-01-01 |
| Ipilimumab-induced Lung Toxicity: Observational Study (NCT02755233) | University of Zurich | 2014-01-01 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (NCT01993719) | National Cancer Institute (NCI) | 2013-12-12 |
| The Jules Bordet Institute Molecular Profiling Program Feasibility Trial (NCT01932489) | Jules Bordet Institute | 2013-12-01 |
| Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (NCT02158520) | Academic and Community Cancer Research United | 2013-10-18 |
| Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer (NCT01902173) | National Cancer Institute (NCI) | 2013-10-08 |
| Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib (NCT01876641) | Mohammed M Milhem | 2013-10-01 |
| Open-Label Study of TPI 287 for Patients With Metastatic Melanoma (NCT01340729) | M.D. Anderson Cancer Center | 2013-09-01 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (NCT01940809) | National Cancer Institute (NCI) | 2013-08-28 |
| Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (NCT01927419) | Bristol-Myers Squibb | 2013-08-23 |
| Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma (NCT01807182) | Fred Hutchinson Cancer Center | 2013-08-20 |
| Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (NCT01495988) | Melanoma Research Foundation Breakthrough Consortium | 2013-08-01 |
| Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques (NCT01558349) | Centre Hospitalier Universitaire de Nīmes | 2013-06-27 |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma (NCT01864538) | ImmunoGenesis | 2013-05-01 |
| HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (NCT01856023) | Clinigen, Inc. | 2013-05-01 |
| Ipilimumab and Imatinib Mesylate in Advanced Cancer (NCT01738139) | M.D. Anderson Cancer Center | 2013-02-19 |
| Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (NCT01689974) | NYU Langone Health | 2013-01-01 |
| Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (NCT01701674) | H. Lee Moffitt Cancer Center and Research Institute | 2012-10-09 |
| Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma (NCT01833767) | Western Regional Medical Center | 2012-10-01 |
| PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (NCT01621490) | Bristol-Myers Squibb | 2012-09-27 |
| Study of Immune Responses in Patients With Metastatic Melanoma (NCT01416844) | Providence Health & Services | 2012-09-01 |
| Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma (NCT01659151) | H. Lee Moffitt Cancer Center and Research Institute | 2012-08-03 |
| Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases (NCT01644591) | M.D. Anderson Cancer Center | 2012-08-02 |
| HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (NCT01683188) | Clinigen, Inc. | 2012-08-01 |
| Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls (NCT01312506) | University of Pittsburgh | 2012-07-01 |
| Peptide Vaccinations Plus GM-CT-01 in Melanoma (NCT01723813) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2012-04-01 |
| A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients (NCT02009397) | University of Louisville | 2012-02-01 |
| Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox (NCT02009384) | University of Louisville | 2012-01-01 |
| Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells (NCT01495572) | National Cancer Institute (NCI) | 2011-12-01 |
| Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors (NCT01878396) | Istituto Oncologico Veneto IRCCS | 2011-12-01 |
| RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA (NCT01497808) | Abramson Cancer Center at Penn Medicine | 2011-11-29 |
| Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer (NCT01457131) | National Cancer Institute (NCI) | 2011-10-06 |
| Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma (NCT01425008) | Millennium Pharmaceuticals, Inc. | 2011-09-15 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (NCT01468818) | National Cancer Institute (NCI) | 2011-09-01 |
| PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy (NCT01415167) | Prometheus Laboratories | 2011-08-01 |
| Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. (NCT01416831) | Providence Health & Services | 2011-07-01 |
| Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma (NCT01369875) | National Cancer Institute (NCI) | 2011-06-17 |
| Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies (NCT01364051) | National Cancer Institute (NCI) | 2011-05-25 |
| Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma (NCT01335009) | Eisai Inc. | 2011-05-16 |
| Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma (NCT01369888) | National Cancer Institute (NCI) | 2011-05-01 |
| Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... (NCT01319565) | National Cancer Institute (NCI) | 2011-03-24 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01258855) | National Cancer Institute (NCI) | 2011-01-18 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (NCT01134614) | National Cancer Institute (NCI) | 2010-12-28 |
| MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes (NCT01273181) | National Cancer Institute (NCI) | 2010-12-01 |
| Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (NCT01743157) | California Pacific Medical Center Research Institute | 2010-12-01 |
| A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma (NCT01212276) | Morphotek | 2010-12-01 |
| CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer (NCT01218867) | National Cancer Institute (NCI) | 2010-11-10 |
| Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (NCT01216696) | National Center for Tumor Diseases, Heidelberg | 2010-11-01 |
| Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (NCT01236573) | National Institutes of Health Clinical Center (CC) | 2010-10-01 |
| Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma (NCT01191034) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2010-08-01 |
| Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer (NCT01160445) | National Cancer Institute (NCI) | 2010-06-01 |
| Of 18F MEL050 Using PET/CT in Metastatic Melanoma (NCT01620749) | Cooperative Research Centre for Biomedical Imaging Development | 2010-06-01 |